New cancer drug INCA32459 enters early human testing
NCT ID NCT05577182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCA32459
What this could lead to
If successful, this could point toward a new treatment option for certain advanced cancers.
What could go wrong
This is a very early Phase 1 trial with only 46 people, focused on safety and dosing. It is too soon to know if the drug works, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncologico Clara Campal
Madrid, 28050, Spain
-
Centro Ricerche Cliniche Di Verona (Crc)
Verona, 37134, Italy
-
Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, 05530, Belgium
-
Cliniques Universitaires Ucl Saint-Luc
Brussels, 01200, Belgium
-
Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, 28223, Spain
-
Ico Institut Catala D Oncologia
L'Hospitalet de Llobregat, 08906, Spain
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, 02650, Belgium
-
Universitair Ziekenhuis Brussel
Jette, 01090, Belgium
-
Universitair Ziekenhuis Gent
Ghent, 09000, Belgium
-
University of Texas Md Anderson Cancer Center
Houston, Texas, 77030, United States